What do systematic reviews say?

Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose)

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 191 participants
  Moderate

Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose)

Sclerotherapy (hypertonic glucose plus polidocanol) showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy (hypertonic glucose) (moderate certainty).

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  RR 0.79 [0.62, 1.01]
  2 studies · 191 participants
  Moderate

Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose)

Sclerotherapy (hypertonic glucose plus polidocanol) showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (hypertonic glucose) (moderate certainty).

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  RR 0.78 [0.51, 1.2]
  2 studies · 191 participants
  Moderate

Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose)

Sclerotherapy (hypertonic glucose plus polidocanol) showed no clear difference in pain ( compared with sclerotherapy (hypertonic glucose) (moderate certainty).

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  RR 1.02 [0.83, 1.24]
  2 studies · 191 participants
  Moderate

Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose)

The review found no eligible studies for this question.

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose)

The review found no eligible studies for this question.

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose)

The review found no eligible studies for this question.

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found